The degree and duration of immunity against herpes simplex virus type 2 (HSV-2) infection of the female genital tract were assessed after intranasal (inl) or intraperitoneal (ip) immunization with a recombinant adenovirus vector expressing HSV glycoprotein B (AdgB8). After intravaginal HSV-2 challenge, control mice rapidly developed disease and displayed high virus titers in vaginal washes. In contrast, virus titers decreased significantly and at similar rates in inl and ip immunized mice and by day 7 were undetectable in vaginal wash samples. Assessment of genital pathology and survival showed that only inl immunization provided long-term protection. Examination of antibodysecreting cells (ASCs) during the decline in vaginal virus titers revealed that gB -specific IgA ASCs were only observed in the genital tissues of inl immunized mice. These results indicate that mucosal immunization provides a high and long-lasting level of immunity from sexually transmitted viral infections of the female genital tract.
The degree and duration of immunity against herpes simplex virus type 2 (HSV-2) infection of the female genital tract were assessed after intranasal (inl) or intraperitoneal (ip) immunization with a recombinant adenovirus vector expressing HSV glycoprotein B (AdgB8). After intravaginal HSV-2 challenge, control mice rapidly developed disease and displayed high virus titers in vaginal washes. In contrast, virus titers decreased significantly and at similar rates in inl and ip immunized mice and by day 7 were undetectable in vaginal wash samples. Assessment of genital pathology and survival showed that only inl immunization provided long-term protection. Examination of antibodysecreting cells (ASCs) during the decline in vaginal virus titers revealed that gB -specific IgA ASCs were only observed in the genital tissues of inl immunized mice. These results indicate that mucosal immunization provides a high and long-lasting level of immunity from sexually transmitted viral infections of the female genital tract.
Protecting the female genital tract against viral sexually samples of mice are inversely related and dependent on the stage of the estrous cycle [13] . These results suggest that the transmitted diseases (STDs), such as those caused by human immunodeficiency virus (HIV) and herpes simplex virus induction of both IgA and IgG will be required to maintain a blanket of humoral immunity in the female genital tract over the (HSV), will likely depend on the presence of both humoral and cellular immune functions [1, 2] . More specifically, the course of the estrous cycle. In addition to humoral immunity, T cells are involved in protecting mucosal tissues as shown by unique immune functions associated with the mucosal immune system can provide optimal protection against STDs [1, 2] .
the role of mucosally derived T cells in protecting the female genital tract against HSV-2 infection [14] . Secretory IgA (sIgA), which is considered the hallmark of mucosal immunity, can mediate protection of mucosal tissues
The immune system has separate compartments in which through inactivation or neutralization of virus at the exterior the development of an immune response can be initiated. The surface of the mucosal epithelium and intracellularly during systemic immune compartment consists of the bone marrow, transcytosis [3 -7] . Furthermore, the level of antibodies in exspleen, and peripheral lymph nodes. The mucosal compartment ternal secretions correlates with protection against diseases of consists of lymphoid aggregates in mucosae, external secretory the respiratory and gastrointestinal tracts [8, 9] . As confirmation glands, and the lymph nodes that drain these tissues [1, 15, 16] . of the importance of mucosal IgA, anti-IgA, but not anti-IgG
The consequence of this compartmentalization is that antigen or IgM antiserum, instilled intranasally (inl) can abrogate imexposure and immune induction within one immune compartmunity against influenza virus infection [10]. ment results in the predominant expression of subsequent imIn the female genital tract, IgG antibodies are an important mune functions within the tissues associated with that compartcomponent of protection, because IgG antibodies specific for ment [1, 13, 15 -17] . As a result, there is an increasing HSV can protect mice against intravaginal HSV type 2 emphasis on the development of novel vaccines designed to (HSV-2) infection [11, 12] . Our studies indicate that the levels induce mucosal-specific immune functions and provide protecof antigen-specific IgA and IgG antibodies in vaginal wash tion against STDs [1] . Several groups pursuing this goal have shown that oral or inl inoculation with live viral or bacterial vectors [14, 18, 19] or conjugates of antigen with cholera toxin [20] groups was done by analysis of variance. tion-competent recombinant adenovirus type 5 vector, AdgB8, has been described [24] . In brief, AdgB8 contains the gB gene from HSV-1 coupled to the SV40 promoter and inserted into the E3 with AdgB8 survived (8/10) the lethal HSV-2 challenge comLong-and short-term resistance to intravaginal HSV-2 infection in mice immunized with AdgB8. Resistance to low-and pared with controls (P £ .005). Of these mice, 60% were completely protected from any overt genital pathology (P £ high-dose intravaginal HSV-2 challenge was examined at short (4 -6 weeks) and long (9 -10 months) periods after AdgB8 .01 vs. unimmunized mice). Of interest, 1 of the ip and 2 of the inl immunized mice developed genital swelling and redness immunization and evaluated by presence and severity of genital pathology (table 1) . Naive mice that served as controls were (genital pathology score £2); however, none of the 3 developed severe symptoms. Further, all mice that survived primary infecunimmunized and age-matched. The severity scores clearly showed that in low-dose challenge experiments both inl and tion were free of overt genital pathology and virus in vaginal wash samples for 3 months after challenge.
Results
ip immunized mice (at 4 -6 weeks) had significantly less genital Figure 2 . Survival of mice immunized with AdgB8 6 weeks before intravaginal HSV-2 infection (2 1 10 4 pfu). Mice were monitored daily for survival and signs of disease. Those with genital pathology scores of 5 were sacrificed. For comparisons between 2 groups, data were analyzed by Fisher's exact test. in, intranasal; ip, intraperitoneal. was assessed in the iliac lymph nodes (ILNs) that drain the Naive 9/9 8.5 (2.1) 10/10 8.3 (2.5) 9 -10 months after genital tissues and in genital tissues (uterus, vagina, and fallo- IgA memory responses, especially in mice immunized 3 weeks † No. of mice that demonstrated overt genital pathology/total (i.e., score §1).
before HSV-2 challenge. In addition, the ILNs of mice immu- ‡ Mean { SD; measured as area under lesion score -day curve for first 6 nized inl (compared with those immunized ip) contained far days.
more IgA ASCs specific for gB both at 3 weeks and 9 months § P õ .05 (AdgB8 immunized vs. unimmunized mice). going a primary response to HSV-2 infection lacked any IgA ASCs and contained only a few IgG ASCs (1% of total) specific for gB of HSV. Of note, only after inl immunization were gBspecific IgA ASCs found in genital tissues. Assessment of IgG pathology than naive mice (P £ .001). However, consistent with the survival data (figure 2), more inl immunized mice ASCs demonstrated that both inl and ip immunized mice were capable of recruiting gB-specific IgG ASCs to the genital tisremained disease-free with significantly lower overall pathology severity scores (0.6 vs. 3.7; P £ .05) than ip immunized sues after HSV-2 infection (table 2) . However, at long periods after ip immunization (9 months), specific IgG ASCs were not mice. Furthermore, when mice immunized 9 -10 months earlier were challenged with a low dose of HSV-2, only inl immunized always detectable in genital tissues. mice had significant resistance on the basis of severity of genital pathology (P £ .05; table 1). Indeed, only 1 inl immunized Discussion mouse had any genital pathology, whereas most of the ip immunized mice developed overt symptoms of infection (4 of 5;
Many different formulations and routes of antigen exposure have been explored for the induction of immunity in the female table 1). The lower pathology severity scores in naive mice at the later challenge time (9 -10 months) compared with the genital tract against HSV and other sexually transmitted pathogens [1, 2, 6, 7, 15, 16] . Several studies have used the inl route scores 4 -6 weeks after challenge are likely due to slower development of genital pathology in aged mice. This increased of immunization to successfully provide humoral immunity in the female genital tract with both IgA and IgG specificities ''natural'' resistance likely accounts for the decreased pathology scores observed in aged inl immunized mice (0.6 vs. 0.1).
[ 18 -20, 22, 25] . Our previous results using inl immunization with AdgB8 also demonstrated the presence of gB-specific IgG The development of genital pathology after a higher challenge dose of HSV-2 was also assessed. At the higher dose, and IgA antibodies in mouse sera and vaginal wash specimens [24, 26] . In contrast, systemic immunization resulted only in both inl and ip immunized mice still displayed significantly less genital pathology than did naive mice (P £ .001) 4 -6 IgG antibodies in vaginal fluids. We also observed that although both inl and ip AdgB8 immunization induced short-term CTL weeks after AdgB8 immunization. In addition, mice immunized inl but not ip were significantly protected 9 -10 months after responses, only inl immunized mice maintained long-lived CTL responses in genital-associated lymphoid tissues [17] . This apAdgB8 immunization (P £ .001). However, the number of inl immunized mice displaying overt pathology increased, as did pears to be a relevant finding since McDermott et al. [14] in adoptive transfer studies demonstrated that immune T cells the overall severity of infection, over that observed at low challenge dose. The severity of infection in ip immunized mice from the genital lymph nodes of mice infected intravaginally with an attenuated strain of HSV-2 could mediate protection did not appear to change from the low challenge dose. As a result, there was no significant difference in severity of patholagainst a subsequent intravaginal HSV-2 challenge.
Here we compared the level of protection after inl or ip mucosal-specific immune functions may become overwhelmed, whereas systemic immune functions can still maintain some immunization at short and long periods against an intravaginal HSV-2 infection. Although no unimmunized mice survived a level of protection during higher challenge doses. These results are in agreement with our earlier observations [13] and those lethal HSV-2 intravaginal challenge, we observed a large degree of protection shortly after AdgB8 immunization, espeof others [21, 23] that showed intranasal immunization is capable of mediating protection against infections of the female cially in mice immunized inl. Moreover, long-term protection was primarily maintained in mice immunized inl. It is conceivgenital tract. We believe these observations to be the first to indicate that inl immunization provides long-lasting and supeable that the mice immunized inl received a larger immune dose, perhaps due to viral replication in the respiratory tract.
rior resistance to intravaginal infection with a sexually transmitted virus compared with ip immunization at the same dose. However, our previous studies indicated that with the same vaccine dose, the initial levels of systemic and mucosal antiConsistent with these observations, Marx et al. [22] showed that intramuscular plus intratracheal or oral, but not intramuscubodies and CTL [17, 24, 26] (except for IgA) were similar with either route of AdgB8 immunization. Thus, the superior lar plus intramuscular, vaccination protected macaques against intravaginal simian immunodeficiency virus infection [22] . The and long-lasting protection observed in inl immunized mice against an intravaginal HSV-2 infection is likely attributable results of McLean et al. [27] also suggest that mucosal immunization provides optimal mucosal protection. In their studies, to other factors, such as the presence of sIgA or long-lived CTL responses [13, 17, 24, 26] . The fact that ip immunized intravaginal immunization of guinea pigs with a genetically disabled HSV-1 virus better protected the animals against intramice are significantly protected for short periods after immunization is in agreement with the proposal [17] that shortly after vaginal infection with wild type virus than did ip immunization. sIgA, which is considered to be of primary importance in immunization there is a period during which immune lymphocytes are present in all immune compartments, regardless of the mucosal immunity, can prevent infection of mucosal tissues [1, 2, 6, 7, 15, 16] . The main activity of IgA has been generally immunization route. Conversely, at longer periods following immunization, memory lymphocytes tend to segregate to tisregarded as its ability to neutralize or prevent attachment of pathogens at the apical surface of mucosal tissues [1, 2, 6, 7, sues related to those in which they were first induced [17] .
The doses of challenge virus that we used likely exceed 15, 16] . However, in vitro [4, 5] and in vivo [3] models have shown that sIgA can form complexes with viruses intracelluthose that would occur naturally, and perhaps as a consequence of this, we observed a dose dependency on severity of infection larly, inhibiting viral replication and subsequently preventing primary or resolving chronic infections. Of interest, in our in inl immunized mice. At a high HSV-2 challenge dose, there was an increase in both the severity of infection and the number studies of immunized mice infected intravaginally with HSV-2, viral replication continued in the genital tract for the first 4 of mice with overt genital pathology. These symptoms were similar to those observed in ip immunized mice, suggesting that days. Thus, AdgB8 immunization did not result in sterile immu-computer program and for providing equipment for analysis of nity in the genital tract. This may have been due to the large ELISPOT data.
challenge doses or because to successfully infect mice intravaginally with HSV-2, it is necessary to induce them into a diestrus-like state. This is achieved following progesterone administration and, as we have observed [13] , this treatment results in
